Literature DB >> 29784636

Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.

Dhifaf Sarhan1, Keli L Hippen2, Amanda Lemire2, Skyler Hying2, Xianghua Luo3,4, Todd Lenvik1, Julie Curtsinger4,5, Zachary Davis1, Bin Zhang1, Sarah Cooley1, Frank Cichocki1, Bruce R Blazar2, Jeffrey S Miller6.   

Abstract

Natural killer (NK) cells are capable of fighting viral infections and cancer. However, these responses are inhibited by immune suppressor cells in the tumor microenvironment. Tumor progression promotes the recruitment and generation of intratumoral regulatory T cells (Treg), associated with a poor prognosis in cancer patients. Here, we show that canonical NK cells are highly susceptible to Treg-mediated suppression, in contrast to highly resistant CD57+ FcεRγ-NKG2C+ adaptive (CD56+CD3-) NK cells that expand in cytomegalovirus exposed individuals. Specifically, Tregs suppressed canonical but not adaptive NK-cell proliferation, IFNγ production, degranulation, and cytotoxicity. Treg-mediated suppression was associated with canonical NK-cell downregulation of TIM3, a receptor that activates NK-cell IFNγ production upon ligand engagement, and upregulation of the NK-cell inhibitory receptors PD-1 and the IL1 receptor family member, IL1R8 (SIGIRR or TIR8). Treg production of the IL1R8 ligand, IL37, contributed to the phenotypic changes and diminished function in Treg-suppressed canonical NK cells. Blocking PD-1, IL1R8, or IL37 abrogated Treg suppression of canonical NK cells while maintaining NK-cell TIM3 expression. Our data uncover new mechanisms of Treg-mediated suppression of canonical NK cells and identify that adaptive NK cells are inherently resistant to Treg suppression. Strategies to enhance the frequency of adaptive NK cells in the tumor microenvironment or to blunt Treg suppression of canonical NK cells will enhance the efficacy of NK-cell cancer immunotherapy. Cancer Immunol Res; 6(7); 766-75. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29784636      PMCID: PMC6030483          DOI: 10.1158/2326-6066.CIR-17-0498

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  38 in total

Review 1.  Natural killer cell memory in infection, inflammation and cancer.

Authors:  Adelheid Cerwenka; Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2016-01-25       Impact factor: 53.106

2.  Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function.

Authors:  Heinrich Schlums; Frank Cichocki; Bianca Tesi; Jakob Theorell; Vivien Beziat; Tim D Holmes; Hongya Han; Samuel C C Chiang; Bree Foley; Kristin Mattsson; Stella Larsson; Marie Schaffer; Karl-Johan Malmberg; Hans-Gustaf Ljunggren; Jeffrey S Miller; Yenan T Bryceson
Journal:  Immunity       Date:  2015-03-17       Impact factor: 31.745

Review 3.  Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Authors:  Douglas Marvel; Dmitry I Gabrilovich
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

4.  Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Authors:  Keli L Hippen; Sarah C Merkel; Dawn K Schirm; Christine M Sieben; Darin Sumstad; Diane M Kadidlo; David H McKenna; Jonathan S Bromberg; Bruce L Levine; James L Riley; Carl H June; Phillip Scheinberg; Daniel C Douek; Jeffrey S Miller; John E Wagner; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

5.  Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8.

Authors:  Suzhao Li; C Preston Neff; Kristina Barber; Jaewoo Hong; Yuchun Luo; Tania Azam; Brent E Palmer; Mayumi Fujita; Cecilia Garlanda; Alberto Mantovani; Soohyun Kim; Charles Anthony Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-05       Impact factor: 11.205

6.  Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.

Authors:  Michelle K Gleason; Todd R Lenvik; Valarie McCullar; Martin Felices; M Shea O'Brien; Sarah A Cooley; Michael R Verneris; Frank Cichocki; Carol J Holman; Angela Panoskaltsis-Mortari; Toshiro Niki; Mitsuomi Hirashima; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

7.  Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Authors:  Rizwan Romee; Maximillian Rosario; Melissa M Berrien-Elliott; Julia A Wagner; Brea A Jewell; Timothy Schappe; Jeffrey W Leong; Sara Abdel-Latif; Stephanie E Schneider; Sarah Willey; Carly C Neal; Liyang Yu; Stephen T Oh; Yi-Shan Lee; Arend Mulder; Frans Claas; Megan A Cooper; Todd A Fehniger
Journal:  Sci Transl Med       Date:  2016-09-21       Impact factor: 17.956

8.  Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.

Authors:  Dhifaf Sarhan; Frank Cichocki; Bin Zhang; Ashley Yingst; Stephen R Spellman; Sarah Cooley; Michael R Verneris; Bruce R Blazar; Jeffrey S Miller
Journal:  Cancer Res       Date:  2016-08-08       Impact factor: 12.701

9.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Authors:  François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre E Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

10.  Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells.

Authors:  Jing-Jing Zhao; Qiu-Zhong Pan; Ke Pan; De-Sheng Weng; Qi-Jing Wang; Jian-Jun Li; Lin Lv; Dan-Dan Wang; Hai-Xia Zheng; Shan-Shan Jiang; Xiao-Fei Zhang; Jian-Chuan Xia
Journal:  Sci Rep       Date:  2014-06-05       Impact factor: 4.379

View more
  31 in total

1.  Inflammatory Networks Linking Oral Microbiome with Systemic Health and Disease.

Authors:  S E Kleinstein; K E Nelson; M Freire
Journal:  J Dent Res       Date:  2020-05-27       Impact factor: 6.116

2.  Innate immunity, inflammation and tumour progression: double-edged swords.

Authors:  A Mantovani; A Ponzetta; A Inforzato; S Jaillon
Journal:  J Intern Med       Date:  2019-03-14       Impact factor: 8.989

Review 3.  Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity.

Authors:  Alberto Mantovani; Charles A Dinarello; Martina Molgora; Cecilia Garlanda
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 4.  NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.064

Review 5.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

Review 6.  IL-37: An anti-inflammatory cytokine with antitumor functions.

Authors:  Yu Mei; Haiyan Liu
Journal:  Cancer Rep (Hoboken)       Date:  2018-11-22

Review 7.  Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside.

Authors:  Karrune V Woan; Jeffrey S Miller
Journal:  Cancer Immunol Res       Date:  2019-11       Impact factor: 11.151

Review 8.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 9.  CAR-NK Cells in the Treatment of Solid Tumors.

Authors:  Ewa Wrona; Maciej Borowiec; Piotr Potemski
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

Review 10.  Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.

Authors:  Natasha Mupeta Kaweme; Fuling Zhou
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.